Zynerba Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ZYNE Zynerba Pharmaceuticals Inc
PDO PIMCO Dynamic Income Opportunities Fund
BOCT Innovator U.S. Equity Buffer ETF™ October
BAC Bank of America Corp
YARIY Yara International ASA
XOM Exxon Mobil Corp
XLF Financial Select Sector SPDR® Fund
XFLT XAI Octagon Floating Rate & Alternative Income Term Trust
WPC WP Carey Inc

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Zynerba Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion syndrome (22q). It is focused on using cannabinoids for treating behavioral symptoms of FXS and 22q. It is developing Zygel (ZYN002), a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol (THC). It uses a patent protected formulation containing ethanol and propylene glycol as solubilizing agents and Transcutol HP as a permeation enhancer. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with FXS, 22q, and autism spectrum disorder (ASD).

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

Apple's stock flirts with best day in four months as analyst explains why bears should show caution

3:02 pm ET September 18, 2023 (MarketWatch)

By Emily Bary

'Sentiment and positioning are both so one-sidedly negative' that positive iPhone demand signals could lift stock 'quickly higher,' says Mizuho

Apple Inc. shares were flirting with their best one-day performance in more than four months after an analyst advised that would-be short sellers show caution in light of iPhone 15 demand indications.

"It remains very early in launch and a lot can change, but my thought heading into [the] iPhone 15 cycle was that sentiment and positioning are both so one-sidedly negative and short that with any delays in delivery times driven more by supply issues vs even consumer demand (OLED screen and...image sensors), that alone could push AAPL stock quickly higher at any point in coming weeks and month," said Mizuho's Jordan Klein, a desk-based analyst with the sales team.

Read:Preorders for the iPhone 15 have begun, and here's a sign they've been 'solid'

He noted that some of Apple's (AAPL) iPhone 15 Pro Max models were showing delivery dates into November, which would be the longest wait time in the past seven years. Meanwhile, China delivery times look better-than-feared given concerns heading into the iPhone's release about a reported ban on iPhone use among Chinese government officials for business purposes.

Don't miss: iPhone 15 preorders: Here are the deals from AT&T, T-Mobile and Verizon

"Hence, while I am not a big fan of the long set-up in AAPL near term, I also would be careful on short side given these pending iPhone 15 data points," Klein wrote.

Apple shares were 2.25% in afternoon trading Monday and on track for their largest single-day percentage gain since June 30, 2023, when they rose 2.31%. However, the stock was up as much as 2.50% earlier in the session, which would have made for its largest one-day gain since May 5, 2023.

BofA analyst Wamsi Mohan took a more cautious stance on iPhone 15 preorder trends, noting that "ship dates for the iPhone 15 Pro and Pro Max models are extended, but somewhat lower (on average) compared to last year at this point in the preorder cycle."

He has a neutral view on Apple shares as the "positive of new product introductions" is outweighed by "a potentially weaker consumer spending environment."

See also: IPO market braces for first tech unicorns in nearly two years

-Emily Bary

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

September 18, 2023 15:02 ET (19:02 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.